Gyre Therapeutics (NASDAQ:GYRE) Announces Quarterly Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) issued its quarterly earnings data on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03), Zacks reports. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Gyre Therapeutics Stock Up 1.4 %

Shares of GYRE stock traded up $0.17 during mid-day trading on Monday, hitting $12.28. The stock had a trading volume of 75,810 shares, compared to its average volume of 74,132. Gyre Therapeutics has a fifty-two week low of $8.26 and a fifty-two week high of $19.00. The company’s 50-day simple moving average is $11.27 and its 200-day simple moving average is $12.30.

Insider Transactions at Gyre Therapeutics

In related news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 38,054 shares of company stock worth $431,157. Company insiders own 19.52% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE boosted its holdings in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 40.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,937 shares of the company’s stock after acquiring an additional 1,996 shares during the period. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. 23.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating on the stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.